BiotechTube

Duloxetine (Cymbalta)

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Dysthymic Disorder

Conditions

Dysthymic Disorder, Depressive Disorder NOS

Trial Timeline

Aug 1, 2006 → Dec 1, 2013

NCT ID
NCT00360724

About Duloxetine (Cymbalta)

Duloxetine (Cymbalta) is a approved stage product being developed by Eli Lilly for Dysthymic Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00360724. Target conditions include Dysthymic Disorder, Depressive Disorder NOS.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00360724ApprovedCompleted

Competing Products

1 competing product in Dysthymic Disorder

See all competitors
ProductCompanyStageHype Score
Desvenlafaxine + PlaceboPfizerApproved
84

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85